Rare diseases set the agenda for paediatric drug development
Many rare conditions begin in childhood, so orphan drug incentives and paediatric rules increasingly pull in the same direction.
In brief
Many rare diseases begin in childhood. How orphan and paediatric incentives combine, and why natural history data drive rare paediatric trials.
- Rare diseases are individually uncommon and collectively significant, and many start in childhood.
- Orphan incentives and paediatric incentives can stack for the same product.
- Natural history data and registries are the backbone of rare paediatric trials.
Rare diseases are individually uncommon and collectively significant, and many of them begin in childhood. A large proportion are genetic, and many are serious, progressive and without approved treatment. That makes the rare disease pipeline one of the main routes through which new medicines reach children.
Overlapping incentives
Orphan drug designation in the US and EU offers its own rewards, including periods of market exclusivity, fee reductions and scientific advice. Sponsors developing for rare paediatric conditions can combine these with paediatric incentives. In the US, the rare pediatric disease priority review voucher has added a further, tradable prize on approval.
This stacking has helped make rare paediatric disease an attractive field for biotech investment, particularly in genetic medicine.
Small populations, hard evidence
With few patients worldwide, sometimes only a few hundred, conventional randomised trials are often impossible. Programmes depend on:
- Natural history studies describing how the disease progresses without treatment.
- External or historical controls, comparing treated patients with similar untreated ones.
- Biomarkers that respond quickly and plausibly predict clinical benefit.
- Patient registries run by advocacy groups and clinical networks.
Regulators have shown flexibility here, including accelerated pathways based on surrogate endpoints. But flexibility cuts both ways: approvals based on limited data leave uncertainty that confirmatory studies must resolve.
Diagnosis is the first barrier
Many children with rare diseases wait years for a diagnosis. Wider use of genomic sequencing, including in newborns and critically ill infants, is shortening that wait. For drug developers it also means finding patients earlier, when treatments are likely to work best.
